Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen's soluble CD4

Executive Summary

Late clinicals for the AIDS drug have "been a struggle," Biogen Chairman and CEO James Vincent told a Jan. 8 Hambrecht & Quist life sciences conference in San Francisco. "Introduction of the parallel track program by the FDA has made it exceedingly difficult to recruit patients for the normal blinded clinical trials necessary to do sound clinical research," Vincent said. Biogen has also found that CD4's binding affinity has been lower in patients than it was in the laboratory. As a result, Biogen has "reduced the size of the clinical research program," Vincent said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel